Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 44 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Messerli FH, Bangalore S, Rimoldi S, Gasowski J, Nussberger J. Are ACE inhibitors acceptable ingredients in polypills?. Lancet 2017;390:26. [Ref.ID 101670]
3.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S, Grossman E. Adverse effects and tolerability of ß blockers. BMJ 2016;353:i3142. [Ref.ID 100378]
5. Cita con resumen
Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 2016;91:51-60. [Ref.ID 99976]
6. Cita con resumen
Bangalore S, Messerli FH. Angiotensin receptor blockers. Fraudulent data: an apology and the fate of ARBs. BMJ 2013;347:20. [Ref.ID 96260]
7. Cita con resumen
Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013;346:13. [Ref.ID 94976]
8.Tiene citas relacionadas
Messerli FH, Bangalore S. Diuretic-based regimens for obese patients?. Lancet 2013;381:512-3. [Ref.ID 94951]
9. Cita con resumen
Messerli FH. Chocolate consumption, cognitive function, and Nobel laureates. N Engl J Med 2012;367:1562-4. [Ref.ID 93892]
10. Cita con resumen
Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL, for the REACH Registry Investigators. ß-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-9. [Ref.ID 93831]
12.Tiene citas relacionadas Cita con resumen
Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 2011;12:65-82. [Ref.ID 89446]
13.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S. FDA drug information that never reaches clinicians. N Engl J Med 2010;362:562. [Ref.ID 87846]
14.Tiene citas relacionadas Cita con resumen
Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008;372:1962-76. [Ref.ID 84666]
15.Tiene citas relacionadas Cita con resumen
Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker - Induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-9. [Ref.ID 84249]
16.Tiene citas relacionadas
Messerli FH, Sulicka J, Gryglewska B. Treatment of hypertension in the elderly. N Engl J Med 2008;359:972-3. [Ref.ID 83861]
17.Tiene citas relacionadas
Bangalore S, Sawyney S, Messerli FH. Siesta, all-cause mortality, and cardiovascular mortality: is there a "siesta" at adjudicating cardiovascular mortality?. Arch Intern Med 2007;167:2143. [Ref.ID 81529]
18.Tiene citas relacionadas Cita con resumen
Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603. [Ref.ID 80810]
19.Tiene citas relacionadas
Bangalore S, Messerli FH. Effect of ramipril on the incidence of diabetes. N Engl J Med 2007;356:522. [Ref.ID 79081]
20.Tiene citas relacionadas
Messerli FH, Beevers G, Franklin SS, Pickering TG. Clinical trials in hypertension. JAMA 2006;296:1463. [Ref.ID 78103]
Seleccionar todas
 
 1 a 20 de 44 siguiente >>